{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:01:17Z","timestamp":1773932477011,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100032164","name":"Univerzita Obrany","doi-asserted-by":"publisher","award":["DZRO-FVZ22-ZHN II"],"award-info":[{"award-number":["DZRO-FVZ22-ZHN II"]}],"id":[{"id":"10.13039\/100032164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-19-0189"],"award-info":[{"award-number":["APVV-19-0189"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["25-16937S"],"award-info":[{"award-number":["25-16937S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014911","name":"Ministerstvo Obrany \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["238323"],"award-info":[{"award-number":["238323"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007594","name":"Univerzita Komenskeho v Bratislave","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118498","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:54:33Z","timestamp":1766076873000},"page":"118498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Novel pyrimidine derivatives as promising antimycobacterial agents"],"prefix":"10.1016","volume":"304","author":[{"given":"Martin","family":"Kufa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Finger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Kovar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Prchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubica","family":"Muckova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Novak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Hympanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Janousek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marketa","family":"Benkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Kunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Bartacek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oto","family":"Pavlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Zdarova-Karasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Odvarkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Savkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Kordulakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"Roh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-7596","authenticated-orcid":false,"given":"Jan","family":"Korabecny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118498_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/AEM.01143-13","article-title":"Winner of the 1952 Nobel Prize for physiology or medicine","volume":"80","author":"Woodruff","year":"2014","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.ejmech.2025.118498_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.blo.0000175887.98112.fe","article-title":"Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. 1944","author":"Schatz","year":"2005","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.ejmech.2025.118498_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/jb.52.4.471-479.1946","article-title":"The role of spontaneous variants in the acquisition of streptomycin resistance by the shigellae","volume":"52","author":"Klein","year":"1946","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejmech.2025.118498_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021147","article-title":"Tuberculosis drug development: history and evolution of the mechanism-based paradigm","volume":"5","author":"Chakraborty","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2025.118498_bib5","article-title":"Mind the gap. Rolling out new drug resistant tuberculosis regimens with limited diagnostic tools","volume":"32","author":"Saluzzo","year":"2023","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.ejmech.2025.118498_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12879-024-09079-5","article-title":"Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019","volume":"24","author":"Lv","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118498_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2229-516X.112228","article-title":"Bedaquiline: first FDA-Approved tuberculosis drug in 40 years","volume":"3","author":"Mahajan","year":"2013","journal-title":"Int. J. Appl. Basic. Med. Res."},{"key":"10.1016\/j.ejmech.2025.118498_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijtb.2020.09.003","article-title":"Pretomanid: the latest USFDA-approved anti-tuberculosis drug","volume":"68","author":"Deb","year":"2021","journal-title":"Indian J. Tubercul."},{"key":"10.1016\/j.ejmech.2025.118498_bib9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-014-0241-5","article-title":"Delamanid: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118498_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2025.118498_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","volume":"20","author":"Dartois","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2025.118498_bib12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1183\/09031936.00162314","article-title":"Novel drugs against tuberculosis: a clinician's perspective","volume":"45","author":"Olaru","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2025.118498_bib13","unstructured":"Global Tuberculosis Report 2024, (n.d.). https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024 (accessed March 10, 2025)."},{"key":"10.1016\/j.ejmech.2025.118498_bib14","first-page":"1","article-title":"Global burden of multidrug-resistant tuberculosis in children and adolescents","author":"Zhong","year":"2025","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ejmech.2025.118498_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40249-023-01107-x","article-title":"Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Salari","year":"2023","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.ejmech.2025.118498_bib16","unstructured":"Global Tuberculosis Report 2023, (n.d.). https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023 (accessed March 27, 2024)."},{"key":"10.1016\/j.ejmech.2025.118498_bib17","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1038\/s41467-023-41937-9","article-title":"Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis","volume":"14","author":"Menzies","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118498_bib18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1473-3099(19)30307-X","article-title":"Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling","volume":"19","author":"Knight","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118498_bib19","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1021\/acs.jmedchem.2c00227","article-title":"Tuberculosis drug discovery: challenges and new Horizons","volume":"65","author":"Fernandes","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118498_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115611","article-title":"2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1","volume":"258","author":"Finger","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118498_bib21","doi-asserted-by":"crossref","first-page":"8841","DOI":"10.1007\/s00253-013-5218-x","article-title":"The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis","volume":"97","author":"Riccardi","year":"2013","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.118498_bib22","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.drudis.2020.07.017","article-title":"Fsp3: a new parameter for drug-likeness","volume":"25","author":"Wei","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118498_bib23","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.rmed.2008.05.004","article-title":"Clinical and radiological features of Mycobacterium kansasii infection and Mycobacterium simiae infection","volume":"102","author":"Shitrit","year":"2008","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejmech.2025.118498_bib24","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.apsb.2025.01.023","article-title":"Revolutionizing tuberculosis treatment: breakthroughs, challenges, and hope on the horizon","volume":"15","author":"Kufa","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118498_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00132-22","article-title":"GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment","volume":"66","author":"Nuermberger","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118498_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01208-21","article-title":"First-in-Human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"Talley","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118498_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04721-22","article-title":"Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis","volume":"11","author":"Xiang","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejmech.2025.118498_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0045-2017","article-title":"Mycobacterium avium complex disease","volume":"5","author":"Daley","year":"2017","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejmech.2025.118498_bib29","article-title":"Non-tuberculous mycobacteria pulmonary disease: a review of trends, risk factors, diagnosis and management","volume":"28","author":"Nqwata","year":"2022","journal-title":"Afr. J. Thorac. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2025.118498_bib30","article-title":"Prevalence of Mycobacterium kansasii in clinical and environmental isolates, a systematic review and meta-analysis","volume":"15","author":"Narimisa","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2025.118498_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02645-20","article-title":"Heterologous production of 1-Tuberculosinyladenosine in Mycobacterium kansasii models pathoevolution towards the transcellular lifestyle of Mycobacterium tuberculosis","volume":"11","author":"Ghanem","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2025.118498_bib32","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/gbe\/evv035","article-title":"Insights on the emergence of Mycobacterium tuberculosis from the analysis of Mycobacterium kansasii","volume":"7","author":"Wang","year":"2015","journal-title":"Genome Biol. Evol."},{"key":"10.1016\/j.ejmech.2025.118498_bib33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/pathogens9080641","article-title":"Preclinical models of nontuberculous mycobacteria infection for early drug discovery and vaccine research","volume":"9","author":"Rampacci","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.ejmech.2025.118498_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/molecules22040535","article-title":"Novel sulfamethoxazole ureas and oxalamide as potential antimycobacterial agents","volume":"22","author":"Kr\u00e1tk\u00fd","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118498_bib35","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00044-010-9405-3","article-title":"Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line","volume":"20","author":"Singh","year":"2011","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118498_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01462-2017","article-title":"Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence","volume":"50","author":"Pontali","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2025.118498_bib37","doi-asserted-by":"crossref","unstructured":"F. Watanabe, K. Furuuchi, K. Hanada, K. Fujiwara, F. Uesugi, M. Hiramatsu, T. Yoshiyama, Y. Shiraishi, A. Kurashima, K. Ohta, K. Morimoto, Pharmacokinetics and adverse effects of clofazimine in the treatment of pulmonary non-tuberculous mycobacterial infection, Antimicrob. Agents Chemother. 66 (n.d.) e00441-22. https:\/\/doi.org\/10.1128\/aac.00441-22.","DOI":"10.1128\/aac.00441-22"},{"key":"10.1016\/j.ejmech.2025.118498_bib38","doi-asserted-by":"crossref","unstructured":"T. Sasaki, E.M. Svensson, X. Wang, Y. Wang, J. Hafkin, M.O. Karlsson, S. Mallikaarjun, Population pharmacokinetic and Concentration-QTc analysis of delamanid in pediatric participants with multidrug-resistant tuberculosis, Antimicrob. Agents Chemother. 66 (n.d.) e01608-21. https:\/\/doi.org\/10.1128\/AAC.01608-21.","DOI":"10.1128\/AAC.01608-21"},{"key":"10.1016\/j.ejmech.2025.118498_bib39","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.bjp.0706678","article-title":"Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin","volume":"147","author":"Alexandrou","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118498_bib40","unstructured":"WHO Consolidated Guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment, (n.d.). https:\/\/www.who.int\/publications-detail-redirect\/9789240007048 (accessed May 26, 2022)."},{"key":"10.1016\/j.ejmech.2025.118498_bib41","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1021\/acs.molpharmaceut.6b00471","article-title":"ADMET evaluation in drug discovery. 16. Predicting hERG blockers by combining multiple pharmacophores and machine learning approaches","volume":"13","author":"Wang","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.118498_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118498_bib43","doi-asserted-by":"crossref","first-page":"13240","DOI":"10.1021\/acs.jmedchem.2c01064","article-title":"Structure-based optimization of coumestan derivatives as polyketide synthase 13-Thioesterase(Pks13-TE) inhibitors with improved hERG profiles for Mycobacterium tuberculosis treatment","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118498_bib44","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1248\/cpb.59.1110","article-title":"A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery","volume":"59","author":"Kawai","year":"2011","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.ejmech.2025.118498_bib45","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bmcl.2006.12.061","article-title":"A quantitative assessment of hERG liability as a function of lipophilicity","volume":"17","author":"Waring","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118498_bib46","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1021\/jm070543k","article-title":"Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships","volume":"51","author":"Shamovsky","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118498_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejmech.2025.118498_bib49","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/dmd.31.8.1035","article-title":"Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties","volume":"31","author":"Wilkening","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2025.118498_bib50","first-page":"1","article-title":"Cell lines: a tool for in vitro drug metabolism studies","volume":"9","author":"Donato","year":"2008","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejmech.2025.118498_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/toxsci\/kfn109","article-title":"Cellular imaging predictions of clinical drug-induced liver injury","volume":"105","author":"Xu","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2025.118498_bib52","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/AAC.45.7.1943-1946.2001","article-title":"Tuberculosis drug screening program, search for new drugs for treatment of tuberculosis","volume":"45","author":"Orme","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118498_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejpb.2019.02.007","article-title":"Molecular simulation as a computational pharmaceutics tool to predict drug solubility, solubilization processes and partitioning","volume":"137","author":"Hossain","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejmech.2025.118498_bib54","first-page":"1987","article-title":"Comparison of commonly used and new methods to determine small molecule non-specific binding to human liver microsomes","volume":"113","author":"Wang","year":"2024","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118498_bib55","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2025.118498_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.108905","article-title":"In vitro metabolism of naphthalene and its alkylated congeners by human and rat liver microsomes via alkyl side chain or aromatic oxidation","volume":"315","author":"Wang","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118498_bib57","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1038\/s41467-019-12844-9","article-title":"Late-stage trifluoromethylthiolation of benzylic C-H bonds","volume":"10","author":"Xu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118498_bib58","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41598-018-20464-4","article-title":"Metabolic hydrolysis of aromatic amides in selected rat, minipig, and human in vitro systems","volume":"8","author":"Bradshaw","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118498_bib59","doi-asserted-by":"crossref","first-page":"14526","DOI":"10.1021\/acs.jmedchem.1c01049","article-title":"Structural and activity relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as antitubercular agents","volume":"64","author":"Fan","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118498_bib60","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1073\/pnas.1700062114","article-title":"MmpL3 is the flippase for mycolic acids in mycobacteria","volume":"114","author":"Xu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118498_bib61","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1128\/AAC.05270-11","article-title":"MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212","volume":"56","author":"La Rosa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118498_bib62","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nchembio.794","article-title":"Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane","volume":"8","author":"Grzegorzewicz","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118498_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial resistance in ESKAPE pathogens","volume":"33","author":"De Oliveira","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2025.118498_bib64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant Gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118498_bib65","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1021\/acs.jmedchem.5b00608","article-title":"Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and thiadiazoles as selective antitubercular agents active against replicating and nonreplicating Mycobacterium tuberculosis","volume":"59","author":"Karabanovich","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118498_bib66","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1021\/acs.jmedchem.9b00912","article-title":"Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and their trifluoromethyl analogues as highly efficient antitubercular agents inhibiting Decaprenylphosphoryl-\u03b2-d-ribofuranose 2\u2019-Oxidase","volume":"62","author":"Karabanovich","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118498_bib67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2008.137","article-title":"Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approach","volume":"6","author":"Piper","year":"2008","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejmech.2025.118498_bib68","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/jps.22792","article-title":"In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods","volume":"101","author":"Poulin","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118498_bib69","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3109\/00498254.2010.500407","article-title":"Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds","volume":"40","author":"Sohlenius-Sternbeck","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2025.118498_bib70","unstructured":"M07-A10 methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically [35, 10 ed.] 1562389874, 1562389882, Dokumen.Pub (n.d.). https:\/\/dokumen.pub\/m07-a10-methods-for-dilution-antimicrobial-susceptibility-tests-for-bacteria-that-grow-aerobically-35-10nbsped-1562389874-1562389882.html (accessed October 29, 2025)."},{"key":"10.1016\/j.ejmech.2025.118498_bib71","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.3390\/molecules20033681","article-title":"Synthesis and disinfection effect of the Pyridine-4-aldoxime based salts","volume":"20","author":"Marek","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118498_bib72","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1016\/j.bmcl.2014.09.060","article-title":"6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity","volume":"24","author":"Malinak","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:30:04Z","timestamp":1773923404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":71,"alternative-id":["S0223523425012632"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118498","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel pyrimidine derivatives as promising antimycobacterial agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118498"}}